Latest updates from ICGI

ICGI will lead the world’s first clinical study using AI on tissue sections to guide the choice of therapy for patients

A Norwegian study led by researchers at the Institute for Cancer Genetics and Informatics at Oslo University Hospital (ICGI) aims to determine whether AI can help doctors decide which patients need chemotherapy after colorectal cancer surgery. The study will involve about 2,000 patients from Norway, United Kingdom and other countries, and will test whether AI can assist clinicians in providing more personalized treatment.

Personalizing treatment for colorectal cancer patients by combining tissue-based biomarkers and ctDNA

Combining artificial intelligence-generated digital pathology tools, conventional histopathological assessment and circulating tumor DNA (ctDNA) analysis can improve treatment stratification of patients with colorectal cancer after surgery. Kerr and colleagues outline this novel paradigm for personalized adjuvant treatment of colorectal cancer in a new publication in Nature Reviews Clinical Oncology.

The Institute for Cancer Genetics and Informatics receives funding from the Norwegian Cancer Society

Research funding from the Norwegian Cancer Society is raised by the Norwegian public and is an important contribution to Norwegian cancer research environments. The number of applications for the annual call for proposals was again numerous this year, and the competition is strong. Our project aims to use artificial intelligence (AI) to improve risk stratification in patients with colorectal cancer that has spread to the liver. We are grateful that the Norwegian Cancer Society has chosen to support our work and ambitions, which will enable the Institute to continue its work to guide in tailoring treatment options for patients with colorectal cancer.